<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03970954</url>
  </required_header>
  <id_info>
    <org_study_id>APHP 180256</org_study_id>
    <nct_id>NCT03970954</nct_id>
  </id_info>
  <brief_title>Low-dose Interleukin-2 in Women With Unexplained Miscarriages</brief_title>
  <acronym>FaCIL-2</acronym>
  <official_title>Regulatory T-cell Induction by Low-dose Interleukin-2 in Women With Unexplained Repeated Spontaneous Early Miscarriages</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iltoo Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the ability of low dose IL-2 to stimulate&#xD;
      peripheral blood Tregs of women with unexplained repeated early spontaneous miscarriages for&#xD;
      development of a therapy to prevent fetal rejection by low dose IL-2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 1 to 3% of women of childbearing age have repeated early spontaneous miscarriages that&#xD;
      may be related to parental chromosomal abnormalities, uterine abnormalities, hormonal causes,&#xD;
      infectious etiology, thrombophilia ... When one of these known causes is excluded, it is&#xD;
      unexplained miscarriages of which half would be due to an immunological deregulation of the&#xD;
      mother causing a decrease of the tolerance to the fetus.&#xD;
&#xD;
      In this context, the stimulation of regulatory T cells (Tregs) by low dose IL-2 is a&#xD;
      therapeutic option with a rational, preclinical and clinical data very favorable.&#xD;
&#xD;
      In humans, low dose IL-2 allows preferential activation of Tregs and is very well tolerated.&#xD;
      Several therapeutic trials have shown its efficiencies.&#xD;
&#xD;
      These elements make it possible to envisage the development of a therapeutic to prevent fetal&#xD;
      rejection by IL2-fd on the women with spontaneous miscarriages by an immunological&#xD;
      deregulation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2021</start_date>
  <completion_date type="Anticipated">February 5, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 5, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)</measure>
    <time_frame>At the day 38 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1]</time_frame>
    <description>Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)</measure>
    <time_frame>At the day 66 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1</time_frame>
    <description>Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)</measure>
    <time_frame>At the day 94 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1</time_frame>
    <description>Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)</measure>
    <time_frame>At the day 122 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1</time_frame>
    <description>Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)</measure>
    <time_frame>At the day 150 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 11</time_frame>
    <description>Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)</measure>
    <time_frame>At the day 38 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1</time_frame>
    <description>Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)</measure>
    <time_frame>At the day 66 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1</time_frame>
    <description>Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)</measure>
    <time_frame>At the day 94 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1</time_frame>
    <description>Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)</measure>
    <time_frame>At the day 122 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1</time_frame>
    <description>Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)</measure>
    <time_frame>At the day 150 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 11</time_frame>
    <description>Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Recurrent Miscarriage</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-dose IL-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low-dose IL-2</intervention_name>
    <description>Subcutaneous injection of low dose of IL-2 for induction course of 5 days, the 10th day after the beginning of periods. At most 5 courses of low dose of IL-2.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>interleukin-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Woman with at least 5 consecutive early miscarriages less than 14 weeks of amenorrhea&#xD;
             and unexplained after the usual check-up;&#xD;
&#xD;
          -  Volunteer to participate in the trial and having given written consent after&#xD;
             appropriate information.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uterine or pelvic abnormality: uterine malformation, intracavitary fibroid, synechiae,&#xD;
             polyp, hydrosalpinx;&#xD;
&#xD;
          -  Balanced translocations in both spouses;&#xD;
&#xD;
          -  Diabetes type I or II;&#xD;
&#xD;
          -  Sickle cell disease;&#xD;
&#xD;
          -  Contraindication to pregnancy;&#xD;
&#xD;
          -  Constitutional or acquired thrombophilia (protein deficit C, S, ATIII, homozygous&#xD;
             factor V or II deficiency, antiphospholipid syndrome, antithyroid antibodies positive,&#xD;
             celiac disease, hyperhomocysteinemia);&#xD;
&#xD;
          -  Ovarian insufficiency (AMH &lt;1 μg/ml);&#xD;
&#xD;
          -  Active HIV or HCV infection;&#xD;
&#xD;
          -  Main known contraindications to treatment with IL-2:&#xD;
&#xD;
          -  Hypersensitivity to the active substance or to any of the excipients;&#xD;
&#xD;
          -  Signs of progressive infection requiring antibiotic therapy;&#xD;
&#xD;
          -  History of organ allograft;&#xD;
&#xD;
          -  Pre-existing autoimmune disease;&#xD;
&#xD;
          -  Leukocytes &lt;4000 / mm3; platelets &lt;100,000 / mm3; hematocrit &lt;30%;&#xD;
&#xD;
          -  hepatic or renal insufficiency;&#xD;
&#xD;
          -  depression;&#xD;
&#xD;
          -  heart failure (ECG);&#xD;
&#xD;
          -  patients with autoimmune disease;&#xD;
&#xD;
          -  patients with an infection (septicemia, bacterial endocarditis, septic&#xD;
             thrombophlebitis, peritonitis and pneumonia);&#xD;
&#xD;
          -  pregnancy;&#xD;
&#xD;
          -  Treatment with immunomodulators, immunosuppressants (class L04A of the ATC&#xD;
             classification), in particular systemic corticosteroids, as well as aspirin and low&#xD;
             molecular weight heparin;&#xD;
&#xD;
          -  No affiliation to a social security;&#xD;
&#xD;
          -  Person who has already been included in this study or in another at the same time;&#xD;
&#xD;
          -  Major incapacitated patient (tutorship / curatorship);&#xD;
&#xD;
          -  Patient with an allergy to taking IL2-fd;&#xD;
&#xD;
          -  Participants who would present professional risk factors (eg ionizing exposure);&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Klatzmann, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pitié Salpètrière APHP Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arsene Mékinian, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Saint Antoine APHP Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilles Kayem, Pr</last_name>
    <role>Study Director</role>
    <affiliation>Trousseau APHP Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Klatzmann, Pr</last_name>
    <phone>+331 42 16 74 61</phone>
    <email>david.klatzmann@upmc.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arsène Mékinian, Dr</last_name>
    <phone>+33 1 48 02 63 96</phone>
    <email>arsene.mekinian@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mekinian</name>
      <address>
        <city>Paris</city>
        <state>Hopital Saint Antoine</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arsene Mekinian, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Olivier Fain, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>roberta Lorenzon, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arsene Mekinian, DR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bornes</name>
      <address>
        <city>Paris</city>
        <state>Hopital Tenon</state>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Bornes, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Marie Bornes, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey rosefort, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kayem</name>
      <address>
        <city>Paris</city>
        <state>Hopital Trousseau</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles Kayem, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Gilles Kayem, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>lucille cedille, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low-dose Interleukin-2</keyword>
  <keyword>Miscarriage</keyword>
  <keyword>Regulatory T cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Abortion, Habitual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

